Subsidiary gets Rs 52.75 cr NPPA demand notice over drug pricing
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pure and Cure Healthcare, Akums' wholly-owned subsidiary, received an NPPA demand notice for Rs 52.75 crore over drug pricing of Lanol 1000 mg injection. The demand covers Rs 18.95 crore overcharging for batches made Dec 2017 to Aug 2024, equal penalty amount, and Rs 14.85 crore interest. Notice was also issued to client Hetero Healthcare (marketer) and Abaris Healthcare. Akums says the marketer bears prime responsibility and their supply agreements hold the marketing entity solely liable for DPCO violations.
Subsidiary faces Rs 52.75 cr NPPA demand but company says primary liability sits with marketer Hetero Healthcare under supply agreements. Could weigh on stock.